These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 24917246)
1. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy. Cong L; Xia ZK; Yang RY Arch Pharm (Weinheim); 2014 Sep; 347(9):609-15. PubMed ID: 24917246 [TBL] [Abstract][Full Text] [Related]
2. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. Ishida W; Mori Y; Lakos G; Sun L; Shan F; Bowes S; Josiah S; Lee WC; Singh J; Ling LE; Varga J J Invest Dermatol; 2006 Aug; 126(8):1733-44. PubMed ID: 16741519 [TBL] [Abstract][Full Text] [Related]
3. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity. Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550 [TBL] [Abstract][Full Text] [Related]
4. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397 [TBL] [Abstract][Full Text] [Related]
5. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer. Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902 [TBL] [Abstract][Full Text] [Related]
6. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase. Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197 [TBL] [Abstract][Full Text] [Related]
7. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats. Liu X; Yu M; Chen Y; Zhang J Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445 [TBL] [Abstract][Full Text] [Related]
9. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). Wermuth PJ; Jimenez SA PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase. Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945 [TBL] [Abstract][Full Text] [Related]
11. Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts. Yamane K; Ihn H; Kubo M; Tamaki K Arthritis Rheum; 2002 Sep; 46(9):2421-8. PubMed ID: 12355490 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors. Zhao LM; Guo Z; Xue YJ; Min JZ; Zhu WJ; Li XY; Piao HR; Jin CH Molecules; 2018 Dec; 23(12):. PubMed ID: 30572609 [TBL] [Abstract][Full Text] [Related]
13. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma. Cui YH; Chen J; Xu T; Tian HL Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417 [TBL] [Abstract][Full Text] [Related]
14. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852 [TBL] [Abstract][Full Text] [Related]
15. Computational investigation of TGF-β receptor inhibitors for treatment of idiopathic pulmonary fibrosis: Field-based QSAR model and molecular dynamics simulation. Li W; Liu X; Muhammad S; Shi J; Meng Y; Wang J Comput Biol Chem; 2018 Oct; 76():139-150. PubMed ID: 30015175 [TBL] [Abstract][Full Text] [Related]
16. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742 [TBL] [Abstract][Full Text] [Related]
17. Potent inhibition of TGF-β signaling pathway regulator Abl: potential therapeutics for hepatic fibrosis. Wang K; Tang Y; Yan F; Zhu J; Li J J Recept Signal Transduct Res; 2015; 35(5):410-9. PubMed ID: 25418123 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5). Li X; Wang L; Long L; Xiao J; Hu Y; Li S Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940 [TBL] [Abstract][Full Text] [Related]
19. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell. Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201 [TBL] [Abstract][Full Text] [Related]
20. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Terashima H; Kato M; Ebisawa M; Kobayashi H; Suzuki K; Nezu Y; Sada T Eur J Pharmacol; 2014 Jul; 734():60-6. PubMed ID: 24726873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]